IP Library › Granted Patent US 12,084,484
Granted Patent B2
US 12,084,484 · App. 16/937,993 · Granted Sep 10, 2024

Interleukin-2 agents and uses thereof

Inventors: Scott Moore Carlson (Boston, MA); Gregory Babcock (Marlborough, MA); Zachary Shriver (Winchester, MA); Boopathy Ramakrishnan (Braintree, MA)
Assignee: Visterra, Inc.
C07K14/55A61P13/12C07K16/246A61K38/00A61K2039/505C07K2319/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,084,484
App. No.
16/937,993
Granted
Sep 10, 2024
Kind
B2
Abstract

IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.

Claims (26)

1. An interleukin-2 (IL-2) variant comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:1031 and

(i) an amino acid substitution H16L, H16N, or I92S, and (ii) amino acid substitutions V69A, Q74P, and C125S.

2. The IL-2 variant of claim 1 , further comprising an amino acid substitution T3A.

3. The IL-2 variant of claim 1 , comprising an amino acid sequence of any one of SEQ ID NOs: 4, 5, 11, 1000, 1001, or 1002.

4. The IL-2 variant of claim 1 , which selectively stimulates regulatory T cells (Tregs).

5. A pharmaceutical composition comprising the IL-2 variant of claim 1 and a pharmaceutically acceptable carrier.

6. A kit comprising the IL-2 variant of claim 1 and instructions for use.

7. The IL-2 variant of claim 1 , comprising the amino acid substitutions H16N, V69A, Q74P, and C125S.

8. The IL-2 variant of claim 1 , comprising the amino acid substitutions H16L, V69A, Q74P, and C125S.

9. The IL-2 variant of claim 1 , comprising the amino acid substitutions V69A, Q74P, I92S, and C125S.

10. The IL-2 variant of claim 1 , comprising the amino acid substitutions T3A, H16N, V69A, Q74P, and C125S.

11. The IL-2 variant of claim 1 , comprising the amino acid substitutions T3A, H16L, V69A, Q74P, and C125S.

12. The IL-2 variant of claim 1 , comprising the amino acid substitutions T3A, V69A, Q74P, I92S, and C125S.

13. The IL-2 variant of claim 3 , comprising the amino acid sequence of SEQ ID NO: 4.

14. The IL-2 variant of claim 3 , comprising the amino acid sequence of SEQ ID NO: 11.

15. The IL-2 variant of claim 3 , comprising the amino acid sequence of SEQ ID NO: 1000.

16. The IL-2 variant of claim 3 , comprising the amino acid sequence of SEQ ID NO: 1001.

17. The IL-2 variant of claim 3 , comprising the amino acid sequence of SEQ ID NO: 1002.

18. An interleukin-2 (IL-2) variant comprising an amino acid sequence having at least 95% sequence identity to SEQ ID NO:1 and

(i) an amino acid substitution H16L, H16N, or I92S, and

(ii) amino acid substitutions V69A and Q74P.

19. The IL-2 variant of claim 18 , comprising the amino acid substitutions H16L, V69A, and Q74P.

20. The IL-2 variant of claim 18 , further comprising an amino acid substitution T3A.

21. A pharmaceutical composition comprising the IL-2 variant of claim 18 and a pharmaceutically acceptable carrier.

22. A kit comprising the IL-2 variant of claim 18 .

23. The IL-2 variant of claim 18 , comprising the amino acid sequence of SEQ ID NO: 5.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2024
From: CARLSON, SCOTT MOORE; BABCOCK, GREGORY; SHRIVER, ZACHARY; RAMAKRISHNAN, BOOPATHY
To: VISTERRA, INC.
Reel/Frame 067440/0038 →
Continuity (3)
Provisional Application 62983061 · Feb 28, 2020
Provisional Application 62879137 · Jul 26, 2019
Related Publication 20210024601A1 · Jan 28, 2021